PT2509409T - Ratinhos que produzem anticorpos de cadeia pesada - Google Patents

Ratinhos que produzem anticorpos de cadeia pesada

Info

Publication number
PT2509409T
PT2509409T PT107908253T PT10790825T PT2509409T PT 2509409 T PT2509409 T PT 2509409T PT 107908253 T PT107908253 T PT 107908253T PT 10790825 T PT10790825 T PT 10790825T PT 2509409 T PT2509409 T PT 2509409T
Authority
PT
Portugal
Prior art keywords
mice
heavy chain
chain antibodies
make heavy
make
Prior art date
Application number
PT107908253T
Other languages
English (en)
Portuguese (pt)
Inventor
Macdonald Lynn
Stevens Sean
J Murphy Andrew
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT2509409T publication Critical patent/PT2509409T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT107908253T 2009-12-10 2010-12-10 Ratinhos que produzem anticorpos de cadeia pesada PT2509409T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28525009P 2009-12-10 2009-12-10

Publications (1)

Publication Number Publication Date
PT2509409T true PT2509409T (pt) 2016-09-29

Family

ID=43534479

Family Applications (2)

Application Number Title Priority Date Filing Date
PT107908253T PT2509409T (pt) 2009-12-10 2010-12-10 Ratinhos que produzem anticorpos de cadeia pesada
PT15177538T PT2954779T (pt) 2009-12-10 2010-12-10 Ratinhos que produzem anticorpos de cadeia pesada

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT15177538T PT2954779T (pt) 2009-12-10 2010-12-10 Ratinhos que produzem anticorpos de cadeia pesada

Country Status (24)

Country Link
US (9) US8754287B2 (enExample)
EP (3) EP2509409B1 (enExample)
JP (5) JP5909449B2 (enExample)
KR (2) KR101553244B1 (enExample)
CN (3) CN102711449B (enExample)
AU (1) AU2010328046C1 (enExample)
CA (1) CA2782936C (enExample)
CY (2) CY1118163T1 (enExample)
DK (2) DK2954779T3 (enExample)
ES (2) ES2595376T3 (enExample)
HR (1) HRP20190820T1 (enExample)
HU (2) HUE030208T2 (enExample)
IL (4) IL220150A0 (enExample)
LT (2) LT2509409T (enExample)
MY (2) MY172472A (enExample)
PL (2) PL2509409T3 (enExample)
PT (2) PT2509409T (enExample)
RS (1) RS58709B1 (enExample)
RU (1) RU2603102C2 (enExample)
SG (2) SG181477A1 (enExample)
SI (2) SI2509409T1 (enExample)
SM (1) SMT201900251T1 (enExample)
TR (1) TR201906488T4 (enExample)
WO (1) WO2011072204A1 (enExample)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523661T3 (es) 2004-07-22 2014-11-28 Erasmus University Medical Center Rotterdam Moléculas de unión
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
NO2792236T3 (enExample) 2009-07-08 2018-04-14
CN102711449B (zh) * 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
ES2641920T3 (es) 2010-03-31 2017-11-14 Ablexis, Llc Ingeniería genética de animales no humanos para la producción de anticuerpos quiméricos
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
ES2946169T3 (es) * 2011-02-25 2023-07-13 Regeneron Pharma Ratones ADAM6
CN103619876A (zh) * 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2758535B1 (en) * 2011-09-19 2016-11-09 Kymab Limited Antibodies, variable domains&chains tailored for human use
GB2501753A (en) * 2012-05-04 2013-11-06 Kymab Ltd Human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20250021626A (ko) * 2011-10-17 2025-02-13 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
AU2012327223A1 (en) * 2011-11-30 2013-06-20 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-FU
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
BR112014015238B1 (pt) 2011-12-20 2022-11-16 Regeneron Pharmaceuticals, Inc Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
LT2883449T (lt) 2012-03-16 2018-05-10 Regeneron Pharmaceuticals, Inc. Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
CN106318951A (zh) 2012-03-16 2017-01-11 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2831245A1 (en) * 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
MX364449B (es) 2012-06-12 2019-04-26 Regeneron Pharma Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
HRP20181866T1 (hr) * 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
ES2839087T3 (es) * 2013-11-12 2021-07-05 Ogd2 Pharma Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
JP6636498B2 (ja) * 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
DK3129400T3 (da) * 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
CN114774466A (zh) 2014-10-22 2022-07-22 克雷森多生物制剂有限公司 转基因小鼠
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
KR102582807B1 (ko) 2014-12-19 2023-09-26 레제네상스 비.브이. 인간 c6에 결합하는 항체 및 이의 용도
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
CA2990015A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US20180230238A1 (en) * 2015-08-24 2018-08-16 Trianni, Inc Enhanced production of immunoglobulins
CN105441455B (zh) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 一种嵌合核酸分子及其在人源化抗体制备中的应用
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
ES2985566T3 (es) 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
TW201805309A (zh) 2016-04-21 2018-02-16 艾伯維史坦森特瑞斯有限責任公司 新穎抗－bmpr1b抗體及使用方法
WO2017196663A1 (en) 2016-05-09 2017-11-16 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
NZ747857A (en) 2016-05-20 2023-01-27 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
SG10201912925SA (en) 2016-10-13 2020-02-27 Massachusetts Inst Technology Antibodies that bind zika virus envelope protein and uses thereof
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
SMT202400189T1 (it) 2017-06-27 2024-07-09 Regeneron Pharma Vettori virali ricombinanti con tropismo modificato e loro usi per l’introduzione bersagliata di materiale genetico nelle cellule umane
SMT202300168T1 (it) 2017-06-27 2023-07-20 Regeneron Pharma Particelle virali ricombinanti con tropismo modificato e loro usi per l’introduzione bersagliata di materiale genetico nelle cellule umane
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
JP6677277B2 (ja) 2017-07-19 2020-04-08 株式会社デンソー 車両用制御装置及び電源供給回路
AU2018302343B2 (en) 2017-07-21 2020-11-26 Trianni, Inc. Single chain vh and heavy chain antibodies
EP3732202A4 (en) 2017-12-28 2022-06-15 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
US12168688B2 (en) 2017-12-28 2024-12-17 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against PD-L1
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP3740507A4 (en) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) * 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
CN111886254B (zh) 2018-03-30 2023-12-08 南京传奇生物科技有限公司 针对lag-3的单结构域抗体及其用途
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
KR20210056288A (ko) 2018-06-01 2021-05-18 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 질환 또는 병태를 치료하기 위한 조성물 및 그의 용도
US12102070B2 (en) * 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
US20210227810A1 (en) * 2018-06-13 2021-07-29 Crystal Bioscience Inc. Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
US12428471B2 (en) * 2018-06-13 2025-09-30 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
CN112673022B (zh) 2018-09-10 2024-07-09 南京传奇生物科技有限公司 针对cd33的单结构域抗体及其构建体
PE20211284A1 (es) 2018-11-16 2021-07-19 Bristol Myers Squibb Co Anticuerpos anti-nkg2a y usos de los mismos
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
MA56035A (fr) 2019-05-24 2022-04-06 Regeneron Pharma Particules virales modifiées et leurs utilisations
JP7726881B2 (ja) 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CN115151573A (zh) 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
EP4112642A4 (en) 2020-02-28 2024-06-26 Shanghai Henlius Biotech, Inc. ANTI-CD137 CONSTRUCTION AND ITS USE
CN111333719B (zh) * 2020-03-16 2021-10-01 西南大学 抗hpv16e7蛋白单抗69a6、杂交瘤细胞及其制备方法和应用
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023529842A (ja) 2020-06-02 2023-07-12 ダイナミキュア バイオテクノロジー エルエルシー 抗ｃｄ９３構築物およびその使用
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
IL298909A (en) 2020-06-17 2023-02-01 Janssen Biotech Inc Materials and methods for the manufacture of pluripotent stem cells
IL299329A (en) * 2020-06-24 2023-02-01 Prothena Biosciences Ltd Antibodies recognizing sortilin
CN116193985A (zh) * 2020-07-13 2023-05-30 加拿大商木曾路生物科技公司 表达重链抗体的转基因动物
CA3190328A1 (en) 2020-07-29 2022-02-03 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
MX2023001708A (es) 2020-08-10 2023-05-04 Janssen Biotech Inc Materiales y métodos para producir linfocitos específicos de virus diseñados mediante bioingeniería.
CN114134144A (zh) * 2020-09-04 2022-03-04 北京仁源欣生生物科技有限公司 一种非人哺乳动物或其子代的制备方法及其应用
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
CN118126190A (zh) 2020-09-28 2024-06-04 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
JP2024500251A (ja) * 2020-12-09 2024-01-05 トリアンニ，インコーポレーテッド 重鎖のみ抗体
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
US12371475B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
KR102836732B1 (ko) 2021-02-19 2025-07-21 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
WO2022177392A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Cd47에 대한 단일 도메인 항체 및 이의 용도
JP7773239B2 (ja) 2021-02-19 2025-11-19 シャペロン インク． Ｐｄ－ｌ１及びｃｄ４７に対する二重特異性単一ドメイン抗体及びその用途
WO2022187863A1 (en) 2021-03-05 2022-09-09 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
TW202300648A (zh) 2021-03-25 2023-01-01 美商當康生物科技有限公司 抗-igfbp7構築體及其用途
JP7555296B2 (ja) * 2021-03-31 2024-09-24 太平洋セメント株式会社 二酸化炭素の固定化方法
EP4333614A4 (en) * 2021-05-05 2025-04-09 Leveragen, Inc. MANIPULATED NON-HUMAN ANIMALS TO PRODUCE ANTIBODIES
CN117651486A (zh) * 2021-05-05 2024-03-05 利威瑞健股份有限公司 用于生产抗体的工程改造的非人动物
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
EP4342908A4 (en) * 2021-06-17 2024-10-23 Fapon Biotech Inc. CHIMERIC IMMUNGLOBULIN
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
PE20241212A1 (es) 2021-11-04 2024-06-06 Regeneron Pharma Particulas virales redirigidas a musculo esqueletico
EP4448578A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
KR20240122784A (ko) 2021-12-17 2024-08-13 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체 및 사용 방법
EP4482861A2 (en) * 2022-02-24 2025-01-01 A & G Pharmaceutical, Inc. Fully human monoclonal antibodies against human progranulin
KR20240163119A (ko) 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. 항-msln 항체 및 사용 방법
CA3256953A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. VECTORS AND METHODS FOR IN VIVO ANTIBODY PRODUCTION
US20250188492A1 (en) 2022-07-22 2025-06-12 Janssen Biotech, Inc. Enhanced Transfer of Genetic Instructions to Effector Immune Cells
IL318636A (en) 2022-07-29 2025-03-01 Regeneron Pharma Viral particles retargeted to transferrin receptor 1
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
WO2024056044A1 (en) * 2022-09-16 2024-03-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals and methods for producing heavy-chain antibodies
WO2024102454A1 (en) * 2022-11-09 2024-05-16 Leveragen, Inc. Engineered non-human animals
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025151796A1 (en) 2024-01-11 2025-07-17 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU781922B2 (en) * 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US6080910A (en) 1997-02-20 2000-06-27 Case Western Reserve University Transgenic knockout animals lacking IgG3
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
KR20050033563A (ko) 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
FR2861255B1 (fr) * 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
ES2364147T3 (es) 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. Polipéptidos de fusión capaces de activar receptores.
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
ES2523661T3 (es) * 2004-07-22 2014-11-28 Erasmus University Medical Center Rotterdam Moléculas de unión
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
EA016609B1 (ru) * 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
RU2435784C2 (ru) 2006-01-25 2011-12-10 Эрасмус Юниверсити Медикал Сентр Роттердам Получение антител из одних тяжелых цепей в трансгенных животных
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
JP2009529917A (ja) * 2006-03-22 2009-08-27 ヴァイラル ロジック システムズ テクノロジー コーポレーション 標的ポリペプチドの同定方法および免疫学的疾患の治療のためのその使用
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
PT2336329E (pt) 2007-06-01 2012-12-24 Omt Inc Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
MX2009013393A (es) 2007-06-08 2010-02-09 Dow Global Technologies Inc Expresion de fragmento de anticuerpo soluble mediante truncamiento de dominio de ch1.
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
WO2009030237A2 (en) 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-rsv antibodies
ES2665068T3 (es) 2008-03-07 2018-04-24 Regeneron Pharmaceuticals, Inc. Ratones derivados de células ES a partir de inyección de un embrión hospedador diploide
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN102711449B (zh) * 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
JP6023667B2 (ja) * 2013-06-26 2016-11-09 矢崎総業株式会社 コネクタ
JP5602929B1 (ja) * 2013-11-08 2014-10-08 株式会社小松製作所 モータグレーダのリッパー装置およびこれを備えたモータグレーダ

Also Published As

Publication number Publication date
EP2954779A1 (en) 2015-12-16
PL2509409T3 (pl) 2017-02-28
US20150197556A1 (en) 2015-07-16
US20150196015A1 (en) 2015-07-16
JP6271450B2 (ja) 2018-01-31
CN102711449B (zh) 2015-01-07
US20150197553A1 (en) 2015-07-16
WO2011072204A1 (en) 2011-06-16
US9888675B2 (en) 2018-02-13
SG10201408181PA (en) 2015-01-29
JP2017140058A (ja) 2017-08-17
DK2509409T3 (en) 2016-11-14
RU2012128856A (ru) 2014-01-20
EP2509409A1 (en) 2012-10-17
US20110145937A1 (en) 2011-06-16
PL2954779T3 (pl) 2019-07-31
ES2724975T3 (es) 2019-09-18
KR20140024970A (ko) 2014-03-03
SMT201900251T1 (it) 2019-07-11
AU2010328046A1 (en) 2012-07-12
JP2013513388A (ja) 2013-04-22
JP6293702B2 (ja) 2018-03-14
DK2954779T3 (da) 2019-05-13
AU2010328046C1 (en) 2018-01-18
LT2509409T (lt) 2016-12-12
TR201906488T4 (tr) 2019-05-21
IL220150A0 (en) 2012-07-31
JP6615830B2 (ja) 2019-12-04
EP3504964A1 (en) 2019-07-03
SI2954779T1 (sl) 2019-06-28
JP5909449B2 (ja) 2016-04-26
IL257822A (en) 2018-04-30
HK1220865A1 (en) 2017-05-19
RU2603102C2 (ru) 2016-11-20
CA2782936A1 (en) 2011-06-16
LT2954779T (lt) 2019-05-27
AU2010328046B2 (en) 2014-07-31
KR20130055556A (ko) 2013-05-28
MY173363A (en) 2020-01-21
CN104131035A (zh) 2014-11-05
CY1121608T1 (el) 2020-05-29
IL257822B (en) 2020-01-30
HUE030208T2 (en) 2017-04-28
US20220201993A1 (en) 2022-06-30
JP2019141095A (ja) 2019-08-29
US20150197555A1 (en) 2015-07-16
IL237819A (en) 2017-03-30
HUE043556T2 (hu) 2019-09-30
SG181477A1 (en) 2012-07-30
CA2782936C (en) 2019-06-18
MY172472A (en) 2019-11-26
KR101430514B1 (ko) 2014-08-19
CY1118163T1 (el) 2017-06-28
JP2015133991A (ja) 2015-07-27
EP2509409B1 (en) 2016-07-27
US8754287B2 (en) 2014-06-17
ES2595376T3 (es) 2016-12-29
IL237818A (en) 2016-08-31
SI2509409T1 (sl) 2016-12-30
US20150197557A1 (en) 2015-07-16
EP2954779B1 (en) 2019-02-06
CN102711449A (zh) 2012-10-03
KR101553244B1 (ko) 2015-09-15
PT2954779T (pt) 2019-05-29
RS58709B1 (sr) 2019-06-28
US11234419B2 (en) 2022-02-01
US20140289876A1 (en) 2014-09-25
CN110079550A (zh) 2019-08-02
JP2015077147A (ja) 2015-04-23
US20150197554A1 (en) 2015-07-16
HRP20190820T1 (hr) 2019-09-20
HK1177100A1 (en) 2013-08-16

Similar Documents

Publication Publication Date Title
IL257822A (en) Mice that produce heavy-chain antibodies
IL292030B1 (en) Mice with restricted immunoglobulin heavy chain
ZA201104545B (en) Anti-siglec-15 antibody
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
BRPI1012694A2 (pt) anticorpos solúveis apenas com cadeia pesada
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0920324D0 (en) Antibodies
GB0905972D0 (en) Antibodies against IL-17BR
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB2473934B (en) Anti-VEEV antibody
GB0911712D0 (en) Antibody
GB0908945D0 (en) Antibodies